A ZIF-8 nanomedicine delivery system co-loaded with doxorubicin and siTDRKH, its preparation method and application

The ZIF-8 nanomedicine delivery system, which co-loads doxorubicin and siTDRKH, solves the problems of tumor cell drug resistance and low siRNA delivery efficiency, achieving highly efficient targeted delivery and synergistic therapy of tumor cells, and enhancing the effect of chemotherapy.

CN121846314BActive Publication Date: 2026-05-26TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
2 Cites 0 Cited by

Patent Information

Application Number
CN202610337080.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-03-19
Publication Date
2026-05-26
Estimated Expiration
2046-03-19

AI Technical Summary

Technical Problem

In existing technologies, tumor cells develop resistance to doxorubicin, limiting its efficacy. At the same time, nucleic acid drugs such as siRNA have poor in vivo stability and low cell delivery efficiency, resulting in poor synergistic therapeutic effects between chemotherapy drugs and nucleic acid molecules.

Method used

The ZIF-8 nanodrug delivery system, which co-loads doxorubicin and siTDRKH, uses the zeolite imidazole ester backbone material ZIF-8 as a carrier to encapsulate doxorubicin and load small interfering RNA targeting the TDRKH gene through electrostatic adsorption. It utilizes pH responsiveness to achieve targeted drug release in the slightly acidic environment of the tumor.

Benefits of technology

It significantly enhanced the sensitivity of breast cancer cells to doxorubicin, improved the efficacy of chemotherapy, reduced drug resistance, and achieved highly efficient targeted delivery and synergistic therapy of tumor cells. In vitro and in vivo experiments showed significant inhibition of tumor growth and good safety.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention discloses a ZIF-8 nanomedicine delivery system co-loaded with doxorubicin and siTDRKH, its preparation method, and its applications, belonging to the fields of biomedicine and nanomaterials technology. The nanomedicine delivery system uses the zeolite imidazole ester framework material ZIF-8 as a carrier. Its porous structure encapsulates the chemotherapeutic drug doxorubicin within the framework, and small interfering RNA targeting the TDRKH gene is loaded onto the surface through electrostatic adsorption. This structure exhibits high pH responsiveness: it remains stable under normal physiological conditions (pH 7.4), preventing premature drug leakage; upon entering the slightly acidic environment of a tumor (pH 6.5) or a lysosomal environment (pH 5.0), the ZIF-8 framework immediately disintegrates, achieving targeted and synergistic release of the loaded drug.
Need to check novelty before this filing date? Find Prior Art